2020 AAN Annual Meeting, Toronto, Canada – canceled due to COVID-19

GenSight Biologics Reports Cash Position as of March 31, 2020 and Provides Operational Update

GenSight Biologics on Track to Submit LUMEVOQ® for European Approval in September 2020 Following Pre-Submission Meeting with EMA

GenSight Biologics Provides Update on Operations in the Context of COVID-19

GenSight Biologics announces presentation of bilateral visual recovery from GS010 (LUMEVOQ™) Phase III trials at the 46th annual meeting of NANOS

2020 Cell & Gene Meeting on the Mediterranean, Barcelona, Spain – cancelled

Bio Europe Spring, Paris, France

46th NANOS Annual Meeting, Amelia Island, Florida, US

GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history

The Quinze-Vingts Hospital and GenSight Biologics announce a first Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France